Effects of Dietary Factors on Lipoprotein-associated Phospholipase A(2) (Lp-PLA (2))

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2011 Aug 27

PMID 21870060

Citations 1

Authors

Cheuk-Kit Wong

Harvey D White

Affiliations

Soon will be listed here.

Abstract

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an enzyme which binds to oxidized LDL and has a pro-inflammatory role in the pathogenesis of atherosclerosis. The Lp-PLA(2) Studies Collaboration showed the relationship between Lp-PLA(2) levels and activity with coronary heart disease and ischemic stroke. Levels and activity of Lp-PLA(2) are reduced by statins. There have been limited studies focused on dietary factors and effects on LpPLA(2). A recent article from the Nurses' Health Study (HNS) and the Health Professionals Follow-up Study (HPFS) has provided interesting insights. In this cross sectional study, a lower LpPLA(2) activity was found to be related to several dietary factors including higher percentage of energy consumed as protein instead of carbohydrate, mild to moderate intake of alcohol, higher mono-unsaturated fat intake instead of carbohydrate, and not being overweight. It is unknown whether changes in Lp-PLA(2) by diet alter cardiovascular risk.

Citing Articles

Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.

Wooten J, Nambi P, Gillard B, Pownall H, Coraza I, Scott L Med Sci Sports Exerc. 2013; 45(6):1043-50.

PMID: 23299761 PMC: 3655089. DOI: 10.1249/MSS.0b013e3182843961.

References

Hatoum I, Nelson J, Cook N, Hu F, Rimm E . Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr. 2010; 91(3):786-93. PMC: 2824159. DOI: 10.3945/ajcn.2009.28870. View

Pedersen M, Koenig W, Christensen J, Schmidt E . The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr. 2008; 48(1):1-5. DOI: 10.1007/s00394-008-0758-z. View

Saougos V, Tambaki A, Kalogirou M, Kostapanos M, Gazi I, Wolfert R . Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007; 27(10):2236-43. DOI: 10.1161/ATVBAHA.107.147280. View

Filippatos T, Gazi I, Liberopoulos E, Athyros V, Elisaf M, Tselepis A . The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis. 2006; 193(2):428-37. DOI: 10.1016/j.atherosclerosis.2006.07.010. View

Davidson M, Corson M, Alberts M, Anderson J, Gorelick P, Jones P . Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008; 101(12A):51F-57F. DOI: 10.1016/j.amjcard.2008.04.019. View

Kolodgie F, Burke A, Skorija K, Ladich E, Kutys R, Makuria A . Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26(11):2523-9. DOI: 10.1161/01.ATV.0000244681.72738.bc. View

Brinton E . Effects of ethanol intake on lipoproteins and atherosclerosis. Curr Opin Lipidol. 2010; 21(4):346-51. DOI: 10.1097/MOL.0b013e32833c1f41. View

Lavi S, McConnell J, Rihal C, Prasad A, Mathew V, Lerman L . Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007; 115(21):2715-21. DOI: 10.1161/CIRCULATIONAHA.106.671420. View

White H, Held C, Stewart R, Watson D, Harrington R, Budaj A . Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J. 2010; 160(4):655-61. DOI: 10.1016/j.ahj.2010.07.006. View

10.

ODonoghue M, Braunwald E, White H, Serruys P, Steg P, Hochman J . Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J. 2011; 162(4):613-619.e1. DOI: 10.1016/j.ahj.2011.07.018. View

11.

Persson M, Nilsson J, Nelson J, Hedblad B, Berglund G . The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis. 2006; 190(2):388-96. DOI: 10.1016/j.atherosclerosis.2006.02.016. View

12.

Muhlestein J, May H, Jensen J, Horne B, Lanman R, Lavasani F . The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol. 2006; 48(2):396-401. DOI: 10.1016/j.jacc.2006.05.009. View

13.

Tzotzas T, Filippatos T, Triantos A, Bruckert E, Tselepis A, Kiortsis D . Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Nutr Metab Cardiovasc Dis. 2007; 18(7):477-82. DOI: 10.1016/j.numecd.2007.04.004. View

14.

Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S . Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010; 375(9725):1536-44. PMC: 2864403. DOI: 10.1016/S0140-6736(10)60319-4. View

15.

Kuvin J, Dave D, Sliney K, Mooney P, Patel A, Kimmelstiel C . Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006; 98(6):743-5. DOI: 10.1016/j.amjcard.2006.04.011. View

16.

Braun L, Davidson M . Lp-PLA2: A new target for statin therapy. Curr Atheroscler Rep. 2010; 12(1):29-33. DOI: 10.1007/s11883-009-0074-y. View

17.

Mannheim D, Herrmann J, Versari D, Gossl M, Meyer F, McConnell J . Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke. 2008; 39(5):1448-55. PMC: 4360896. DOI: 10.1161/STROKEAHA.107.503193. View

18.

Schaefer E, McNamara J, Asztalos B, Tayler T, Daly J, Gleason J . Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol. 2005; 95(9):1025-32. DOI: 10.1016/j.amjcard.2005.01.023. View

19.

Wolfe B, Giovannetti P . Short-term effects of substituting protein for carbohydrate in the diets of moderately hypercholesterolemic human subjects. Metabolism. 1991; 40(4):338-43. DOI: 10.1016/0026-0495(91)90142-j. View

20.

Stewart R, White H . The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis. Curr Atheroscler Rep. 2011; 13(2):132-7. DOI: 10.1007/s11883-010-0158-8. View